coagulation factor XIII (Tretten®)

OFFICE  ADMINISTRATION

Indications for Prior Authorization:

  • Prophylaxis of bleeding episodes in adults and children with congenital Factor XIII A-subunit deficiency

The drug is not approved for any use not mentioned above including:

  • Congenital Factor XIII B-subunit deficiency

Dosing:

  • The recommended dose is 35 IU/kg body weight by IV injection once monthly

Approval:

One year


  

Last review date: May 1, 2014

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.